Andrew Berens
Stock Analyst at Leerink Partners
(1.08)
# 3,602
Out of 4,855 analysts
124
Total ratings
46.46%
Success rate
-10.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $7.53 | +19.52% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $2.50 | +140.00% | 3 | Apr 2, 2025 | |
| OKUR OnKure Therapeutics | Initiates: Outperform | $33 | $2.88 | +1,045.83% | 1 | Dec 5, 2024 | |
| COGT Cogent Biosciences | Maintains: Outperform | $14 → $15 | $6.80 | +120.59% | 4 | Jun 13, 2022 | |
| ELEV Elevation Oncology | Downgrades: Market Perform | $9 → $1 | $0.32 | +212.60% | 5 | Mar 21, 2025 | |
| ZYME Zymeworks | Upgrades: Outperform | $10 → $25 | $12.60 | +98.41% | 10 | Nov 7, 2024 | |
| GILD Gilead Sciences | Upgrades: Outperform | $74 → $96 | $112.46 | -14.64% | 1 | Oct 21, 2024 | |
| AGIO Agios Pharmaceuticals | Downgrades: Market Perform | $60 → $56 | $34.32 | +63.17% | 11 | Sep 27, 2024 | |
| CELC Celcuity | Initiates: Outperform | $29 | $13.07 | +121.97% | 1 | Jul 22, 2024 | |
| BPMC Blueprint Medicines | Upgrades: Market Perform | $50 → $97 | $127.85 | -24.13% | 24 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $69 → $110 | $78.06 | +40.92% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $68.76 | +13.44% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $48 | $56.21 | -14.61% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $12.78 | +119.09% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $72.88 | +8.40% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.52 | +1,676.32% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $1.56 | +1,823.08% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $9.08 | +175.33% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $6.51 | +514.44% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $1.73 | +3,772.83% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $5.01 | +299.20% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.26 | +486.85% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $9.02 | -11.31% | 7 | Jul 14, 2017 |
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $7.53
Upside: +19.52%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $2.50
Upside: +140.00%
OnKure Therapeutics
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.88
Upside: +1,045.83%
Cogent Biosciences
Jun 13, 2022
Maintains: Outperform
Price Target: $14 → $15
Current: $6.80
Upside: +120.59%
Elevation Oncology
Mar 21, 2025
Downgrades: Market Perform
Price Target: $9 → $1
Current: $0.32
Upside: +212.60%
Zymeworks
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $12.60
Upside: +98.41%
Gilead Sciences
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $112.46
Upside: -14.64%
Agios Pharmaceuticals
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $34.32
Upside: +63.17%
Celcuity
Jul 22, 2024
Initiates: Outperform
Price Target: $29
Current: $13.07
Upside: +121.97%
Blueprint Medicines
May 6, 2024
Upgrades: Market Perform
Price Target: $50 → $97
Current: $127.85
Upside: -24.13%
Apr 1, 2024
Upgrades: Outperform
Price Target: $69 → $110
Current: $78.06
Upside: +40.92%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $68.76
Upside: +13.44%
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $56.21
Upside: -14.61%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $12.78
Upside: +119.09%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $72.88
Upside: +8.40%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.52
Upside: +1,676.32%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $1.56
Upside: +1,823.08%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $9.08
Upside: +175.33%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $6.51
Upside: +514.44%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $1.73
Upside: +3,772.83%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $5.01
Upside: +299.20%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $4.26
Upside: +486.85%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $9.02
Upside: -11.31%